PAI-1 4G/5G gene polymorphism is associated with angiographic patency in ST-elevation myocardial infarction patients treated with thrombolytic therapy

Coronary Artery Disease

Volumn 23, Issue 6, 2012, Pages 400-403

  Ozkan, Bugra ^a   Cagliyan, Caglar E ^b   Elbasan, Zafer ^b   Uysal, Onur K ^c   Kalkan, Gulhan Y ^b   Bozkurt, Mehmet ^d   Tekin, Kamuran ^b   Bozdogan, Sevcan T ^b   Ozalp, Ozge ^b   Duran, Mustafa ^c   Sahin, Durmus Y ^b   Cayli, Murat ^b  

^a Burdur Bucak State Hospital   (Turkey)

^b ADANA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c Kayseri Education and Research Hospital ^*  (Turkey)

^d Sincan State Hospital   (Turkey)

Author keywords

PAI 1 4G 5G polymorphism; ST elevation myocardial infarction; thrombolytic therapy

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ANGIOCARDIOGRAPHY; ARTERY BLOOD FLOW; ARTICLE; BLOOD CLOT LYSIS; CARDIAC PATIENT; CONTROLLED STUDY; CORONARY ARTERY; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INFARCT RELATED ARTERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; CORONARY ANGIOGRAPHY; CORONARY VESSELS; FEMALE; FIBRINOLYTIC AGENTS; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RISK FACTORS; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84864852100     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3283576a77     Document Type: Article

References (26)

1. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343:311-322.
2. Raitt MH, Maynard C, Wagner GS, Cerqueira MD, Selvester RH, Weaver WD. Relation between symptom duration before thrombolytic therapy and final myocardial infarct size. Circulation 1996; 93:48-53. (Pubitemid 26006567)
3. Maggioni AP, Franzosi MG, Farina ML, Santoro E, Celani MG, Ricci S, et al. Cerebrovascular events after myocardial infarction: analysis of the GISSI trial. BMJ 1991; 302:1428-1431.
4. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673-682.
5. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329:1615-1622.
6. Van de Werf F. Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. Lancet 1989; 1:1367-1369.
7. Vogt A, von Essen R, Tebbe U, Feuerer W, Appel KF, Neuhaus KL. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993; 21: 1391-1395. (Pubitemid 23138707)
8. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation 1993; 87:1829-1839. (Pubitemid 23165624)
9. Karagounis L, Sorensen SG, Menlove RL, Moreno F, Anderson JL. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second multicenter thrombolysis trial of eminase in acute myocardial infarction. J Am Coll Cardiol 1992; 19:1-10.
10. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med 1993; 118:956-963. (Pubitemid 23164134)
11. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2:533-537. (Pubitemid 16054632)
12. Hamsten A, de Faire U,Walldius G, Dahlén G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2:3-9. (Pubitemid 17083665)
13. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004; 91:861-872. (Pubitemid 38647488)
14. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341:1165-1168. (Pubitemid 23137110)
15. Anderson JL, Sorensen SG, Moreno FL, Hackworthy RA, Browne KF, Dale HT, et al. Multicenter patency trial of intravenous anistreplase compared with streptokinase in acute myocardial infarction. The TEAM-2 Study Investigators. Circulation 1991; 83:126-140.
16. Matsubara Y, Murata M, Isshiki I, Watanabe R, Zama T, Watanabe G, et al. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels. Int J Hematol 1999; 69:43-47.
17. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 1997; 17:33-37. (Pubitemid 27057321)
18. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342:1792-1801. (Pubitemid 30390240)
19. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 2001; 104:3063-3068. (Pubitemid 34014058)
20. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99:3050-3055. (Pubitemid 29270436)
21. Sibbing D, von Beckerath O, von Beckerath N, KochW, Mehilli J, Schwaiger M, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction. Blood Coagul Fibrinolysis 2005; 16:511-515. (Pubitemid 41794946)
22. Ferreira R. The reduction of infarct size - forty years of research. Rev Port Cardiol 2010; 29:1037-1053.
23. Appelbaum E, Abraham JM, Pride YB, Harrigan CJ, Peters DC, Biller LH, et al. Association of thrombolysis in myocardial infarction myocardial perfusion grade with cardiovascular magnetic resonance measures of infarct architecture after primary percutaneous coronary intervention for STsegment elevation myocardial infarction. Am Heart J 2009; 158:84-91.
24. Boersma E, Maas AC, Deckers JW. Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771-775. (Pubitemid 26308479)
25. Holmes DR, Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial. Global utilization of streptokinase and tissue plasminogen activator for occluded arteries. J Am Coll Cardiol 1995; 25:10S-17S.
26. Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, et al. Prehospital-initiated vs. hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270:1211-1216. (Pubitemid 23262351)